性能参数 |
|||
产品名称 |
Trametinib |
||
规格 |
0mM (in 1mL DMSO) 50mg 200mg 500mg |
||
货号 |
GOY-Y2962 |
||
含量 |
>98.00% |
||
CAS |
871700-17-3 |
||
别名 |
Trametinib, GSK-1120212, GSK1120212, Mekinist, JTP74057, JTP-74057 |
|
|
化学名 |
N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide |
分子式 |
C26H23FIN5O4 |
分子量 |
分子量 615.39 |
溶解度 |
≥ 15.38mg/mL in DMSO |
储存条件 |
Store at -20°C |
General tips |
|
用途 |
仅供科研 |
价格 |
电询 |
|
|||
详细内容 |
Trametinib (also known as GSK1120212 or JTP 74057), originally identified as a p15 inductive compound, is a novel and potent allosteric inhibitor of MEK kinase, which exhibits ATP non-competitive inhibition against MEK1 and MEK2 kinase. It has demonstrated broad antitumor activities in a variety of tumor xgenograft models, including HT-29 and COLO205 colorectal tumor cell lines. Trametinib induces expression of p15 and p27, reduces cyclin D1 levels, and causes dephosphorylation of RB protein and G1-phase arrest with a reduction of TS expression in HT-29 cells. It also effectively inhibits p-ERK 1/2 resulting in cell growth inhibition in tumor cell lines harboring B-RAF mutant. |
公司正在销售的产品:
无水乙醚 GR,99% 劳森试剂 97% 乙醚 for HPLC, >99.0%(GC),含2%乙醇作稳定剂 3-羟基苯硫酚 96% >99.0% (GC) 苯硫基乙酸甲酯 97% OP-4乳化剂 亲油,羟值150±10 4-甲氧基茴香硫醚 98% O113278-500ml OP-10乳化剂 2-羟基茴香硫醚 98% 焦亚硫酸钾 AR,95.0% 4-甲硫基苯乙酮 97% |
PD01760781mg 5mg 10mg 20mg>98.00%Cas No. 248922-46-5C23H30F2N2O (E/Z)-Sivopixant5 mg 10 mg 25 mg 50 mg 100 mg>98.00%Cas No. 1640808-39-4C25H22ClN5O5 (Rac)-NMDAR antagonist 15mg 10mg 25mg 50mg 100mg>98.00%Cas No. 2435557-99-4C20H20BrN3O2 (R)-Posenacaftor sodium5 mg 10 mg 25 mg 50 mg 100 mg>98.00%Cas No. 2095064-09-6C27H26NNaO5 (R)-Lanicemine5 mg 10 mg 25 mg 50 mg 100 mg>98.00%Cas No. 190581-71-6C13H14N2 |
传真号码:021-39596320 021-39921927
QQ: 3004918891 3004905818 3004901493
移动电话:18321818584 15026555973
地址:上海松江新砖公路1155号
产品均为实验试剂,仅供科研实验使用,非药品、非食品、不可用于动物及人体!